Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 5/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | IDO1 | P14902 | 1/20 | 0.48 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.47 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.47 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.46 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.46 |
| ▸ | ANPEP | P15144 | 1/20 | 0.45 |
| ▸ | EPOR | P19235 | 1/20 | 0.44 |
| ▸ | CTSL | P07711 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1347691 | 0.98 | LTA4H (0.54) | LTA4HALDH1A1IDO1SLC1A3SLC1A1 | |
| Hydrochloric Acid SCHEMBL27452128 | 0.92 | LTA4H (0.56) | LTA4HALDH1A1IDO1SLC1A3SLC1A1 | |
| SCHEMBL10441465 | 0.92 | IDO1 (0.53) | LTA4HALDH1A1IDO1SLC1A3SLC1A1 | |
| SCHEMBL4161005 | 0.92 | IDO1 (0.53) | LTA4HALDH1A1IDO1SLC1A3SLC1A1 | |
| Hydrochloric Acid SCHEMBL28986973 | 0.91 | IDO1 (0.52) | LTA4HALDH1A1IDO1SLC1A3SLC1A1 | |
| Hydrochloric Acid SCHEMBL9073812 | 0.91 | IDO1 (0.52) | LTA4HALDH1A1IDO1SLC1A3SLC1A1 | |
| SCHEMBL27324538 | 0.88 | LTA4H (0.59) | LTA4HALDH1A1SLC1A3SLC1A1 | |
| SCHEMBL10994023 | 0.88 | SLC1A1 (0.52) | LTA4HALDH1A1IDO1SLC1A3SLC1A1 | |
| SCHEMBL676303 | 0.88 | SLC1A1 (0.52) | LTA4HALDH1A1IDO1SLC1A3SLC1A1 | |
| SCHEMBL31286410 | 0.88 | IDO1 (0.50) | LTA4HALDH1A1IDO1SLC1A3SLC1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116924943-A | Preparation and application of amino acid isocyanate derivative | 中国科学院理化技术研究所 | 2023-10-24 | — | — | CN | disclosed |
| US-8063094-B2 | Anti-cytokine heterocyclic compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-11-22 | — | — | US | disclosed |
| US-20110053955-A1 | ANTI-CYTOKINE HETEROCYCLIC COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-03-03 | — | — | US | disclosed |
| US-4575503-A | ANGIOTENSIN CONVERTING ENZYME INHIBITOR, HYPOTENSIVE | CIBA-GEIGY CORPORATION (US) | 1986-03-11 | — | — | US | disclosed |
| US-4537885-A | SUBSTITUTED 1-CARBOXY-3-(CARBOXYMETHYLAMINO)-2-ONE DERIVATIVES, ANGIOTENSIN CONVERTING ENZYME INHIBITORS | CIBA GEIGY CORPORATION (US) | 1985-08-27 | — | — | US | disclosed |
| US-4470988-A | HYPOTENSIVE AGENTS, ENZYME INHIBITOR, CARDIAC DISORDERS | CIBA-GEIGY CORPORATION (US) | 1984-09-11 | — | — | US | disclosed |
| EP-0010405-A1 | Stable immunochemical assay reagent for the determination of haptens, and assay method using said reagent | TEIKOKU HORMONE MFG. CO., LTD. (JP) | 1980-04-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110053955-A1 | ANTI-CYTOKINE HETEROCYCLIC COMPOUNDS | MAPKAPK2, IL2, MAP3K2 | LTA4H 3334/4885ALDH1A1 3398/4885IDO1 2305/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.